DrugPipeline.net has announced the addition of “Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017” research report to their website www.DrugPipeline.net

Bangalore, India -- (SBWire) -- 04/16/2018 --Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017 report provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, with symptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior.

Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking.

The size of these pipelines ranges from 11 products in Tourette syndrome to 191 in depression. Across all four of these indications, however, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Spanning over 254 pages "Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017" report covers Executive Summary, Introduction, Neuropsychiatric Disorder Cluster Report Coverage, Therapeutics Development, Therapeutics Assessment, Dormant Projects, Appendix.

For more information Visit at: https://www.drugpipeline.net/gbi-research/neuropsychiatric-disorder-cluster-drug-development-pipeline-review-2017

Find all Pharma and Healthcare Reports at - http://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Global Dermatology Drugs Market to 2023 - Growth Driven by Increased Uptake of Interleukin Receptor Inhibitors for Psoriasis and Atopic Dermatitis - Visit at - https://www.drugpipeline.net/gbi-research/global-dermatology-drugs-market-2023-growth-driven-increased-uptake-interleukin

Global Ophthalmology Drugs Market to 2023 - Angiogenesis Inhibitors in wAMD Set to Retain High Market Share, While Expansive Pipeline for Glaucoma Leads the Research Landscape - Visit at - https://www.drugpipeline.net/gbi-research/global-ophthalmology-drugs-market-2023-angiogenesis-inhibitors-wamd-set-retain-high

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.